{"name":"Won Seog Kim","slug":"won-seog-kim","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ACHOP","genericName":"ACHOP","slug":"achop","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ACHOP","genericName":"ACHOP","slug":"achop","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1fNEdoc1hNNDZSR1gwRFhQRkx3bFVTSW15QmtrNzVibTRRTVR6YXJHN1pMcWluOGEtSjAya1diVEJsbmxLQzdhdUczZGtxcXZ6a0xrV2k2NWZlck94Q2pBa2RsWVZ6UGRTR2RmcGxR0gFyQVVfeXFMUE5FNFphdTNaMWRsVnRzNmN1b01RMXJUMDFZVmxodGIycXBvU0NxaDVTNkg2dlNHYm5mMERaWnZIZE16bkpYOGN6SnB2OWFZN1czUDVzaG15MEl4V3N1V1l0bDhNa3l4Y1dnWDdFaHZfTFJB?oc=5","date":"2026-03-27","type":"trial","source":"koreabiomed.com","summary":"ImmunOncia reports phase 2 data for Danburstotug in NK/T-cell lymphoma - koreabiomed.com","headline":"ImmunOncia reports phase 2 data for Danburstotug in NK/T-cell lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5jVWVEZlFjaUpnam9CUUpGTmNST1VYMnRvQ01iTnQzRUt3ZG5xb185WmhxQ1Jsdm9fNG9NdlFuUnEtWUl4bHZsY0VDaDFSTlVPQ2JBWEZ0eFNpS29OazZaM1ZPNndIanN2STEzRmd30gFyQVVfeXFMTmJMSnNCUTJ6YV92bThzd211OVdKNTJmRTBSX1hYOU1JSFZjQU94Sk5JdFc1TUZkTS1CbWliNEUyTDlYMzFHel9IdjdoOHpMTFRCekVYeUJyYTZqODBKUUM5Szk0RG00aUFVQlU0V2RXZm1R?oc=5","date":"2026-03-16","type":"pipeline","source":"koreabiomed.com","summary":"300 oncology experts discuss advances in 5 cancers at Takeda summit in Seoul - koreabiomed.com","headline":"300 oncology experts discuss advances in 5 cancers at Takeda summit in Seoul","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9ncGMyMU0wclpUSUdLc2VUeV92R1JRdW1fTnpXQ1JidWR0bExWNlFrQTVEQUwyeEs0bjV3UjFNNWpVZ1pGa2pXSVJlY0RqRHVDSktMeXRoRko5R0wwaGhhWUFKTnQ5dzB1VjdDd0R30gFyQVVfeXFMTno0TFRtLTg3eERpU3EwM0laWi1oVmJ3YWp3dURsRTcxdzJHeWtlTXVWcFFkWUd0MVI2cGc4b1BZLV9ra1R1YkRGT0c2al96NnM2WU9RQ05Xd0labml3ZmVLeGl0UFZwTVg5Ri1fZHRIalBn?oc=5","date":"2025-12-10","type":"pipeline","source":"koreabiomed.com","summary":"[ASH 2025] GC Cell’s allogeneic CAR-NK therapy shows promising safety and efficacy in relapsed/refractory T-cell malignancies - koreabiomed.com","headline":"[ASH 2025] GC Cell’s allogeneic CAR-NK therapy shows promising safety and efficacy in relapsed/refractory T-cell maligna","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBMS3hjWTNIcE5DVkxYeE54OF95b0xYNHZjUFE2VkNKS21oSXktRDh2S1dEQXhOTUM0NkNRZ0xhOHFTRU9CUkVzcms5SUJRejRRV1dIWHdRNURzWVh4VHlUMm9lRUNQQ3N6d0NxLUhR0gFyQVVfeXFMUEp5WTRSU0pkYjZyNXozVHUtd1NlSVJMd3QtSXFGQld2cXF6eEI0SEhaU1l3enROTUgwcTlXVXdTeFF0LWFWOFUydGxpMzM0WDdJcS1xd2RkZWM5dlJxUmdTdk8tYWFXVWNCTGdpNXNfOGRB?oc=5","date":"2025-03-31","type":"pipeline","source":"koreabiomed.com","summary":"Boryung CEO charts bold future with space healthcare vision, reinforces pharma core - koreabiomed.com","headline":"Boryung CEO charts bold future with space healthcare vision, reinforces pharma core","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9mb0oxemlVQXFYRmtZRlR0QnFQOFpIQjdfdDFRR0x1VHhlXzRwM2FLb19VUGtJSTFxUkRjWUw1ZTRDU1JUdTVsM3ZHckVDMVoxZFJsWFFWRlZvdkxvcllN?oc=5","date":"2025-03-17","type":"trial","source":"nature.com","summary":"Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial - nature.com","headline":"Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5acEw1WVlGQUcxbE9vUXNhZVVYZ3RBb1YyT1BXZjBiRUFvLVNVZklfRkVtejltSlczcXc2RXpOY3FOSGxBMFk0Yzc0TTFvVG9WVXJOTHRDZXliRmV5elFoRw?oc=5","date":"2022-07-13","type":"pipeline","source":"NEJM","summary":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma - NEJM","headline":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9FUnFVcDdWd2swMGs5eEdsY3JCdG5mOTMzcXYtOTNySWVCMWxJcFZ5aFBTa2c3RXgxYWcwQ2Vra05wdnRGbG1SZTFjeXplbVgzUHFHLVRLTzFVQzNIUHZqNjdNUThfTE5lN3lFbdIBcEFVX3lxTFBTSHdYUHlGUGF5b1EwaDFmQmJlTkk0NWV4ZDhnMEI4a3NoQ011aE9XeVFHd2NZd3AtUlRqaFBsX3RzbVN6QkJoTVJTVllGSXk1bkEwV0NFWGt2NU82ZS0yN2syOVR3NVkzeVpXelhJa0M?oc=5","date":"2017-09-14","type":"pipeline","source":"koreabiomed.com","summary":"Opdivo vs. Keytruda - which will doctors choose? - koreabiomed.com","headline":"Opdivo vs. Keytruda - which will doctors choose?","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}